Yelak Biru notes that there are many resources and support groups that can help patients with multiple myeloma and provides some words of encouragement.

Yelak Biru discusses his experience in gathering information when he was diagnosed with multiple myeloma in 1995 versus the information landscape today, and addresses what he wishes he had known at the time.

Yelak Biru identifies some pervasive misconceptions and common barriers that exist regarding clinical trials.

Patients with multiple myeloma face many unique challenges and can significantly benefit from enlisting the help of a navigator.

Yelak Biru says that nurse navigators are a critical component of the treatment team. Hear why.

Yelak Biru stresses the importance of paying it forward and sharing your knowledge with others in regard to patient advocacy.

Yelak Biru believes that a cancer diagnosis affects a person's entire family and support network, and notes that there are various ways for patients with cancer to involve and inform their families about their treatment.

Yelak Biru describes how patients can benefit from becoming involved in patient advocacy.

Yelak Biru provides some direction for people who are interested in becoming a patient advocate.

Yelak Biru explains the role of the patient advocate and what inspired him to become one.

Yelak Biru recalls being initially diagnosed with stage 3 multiple myeloma at age 25, and his subsequent relapse. Working with oncology teams, educating himself through support groups, and getting involved in associations as a speaker, Yelak has integrated myeloma into his life by becoming a patient advocate.

An in-depth overview of multiple myeloma and the unmet needs that patients with multiple myeloma face, as patient advocates from the US, Canada, and Europe assembled in Lisbon, Portugal for the first annual global Patient Leadership Council Multiple Myeloma Roundtable

Yelak Biru, who was diagnosed with multiple myeloma at age 25, shares his inspiring story, including the top 3 lessons that helped him remain positive.

Yelak Biru offers his feedback on the new medications that were approved in 2015, and the importance of knowing how these medicines will be used and which types of patients will be treated with them.

Yelak Biru points out the importance of patients being able to set up an ongoing dialogue with their providers outside of the formal appointment settings.

This article summarizes the views of the patients regarding their experiences with current treatments and other issues related to cancer care.

Now more than ever, patients with multiple myeloma have unprecedented numbers of treatment options to choose from for their deadly plasma-cell neoplastic diseases.

Yelak Biru explains what patients need to know in order to better understand and stay on track with their medications.

Yelak Biru identifies similarities and differences between oral and physician-administered drugs, noting that patient-provider relationships are even more crucial when dealing with an oral drug regimen.